Alexandria Venture Investments

What Alexandria Venture Investments does

Alexandria Venture Investments (Alexandria Ventures®) is the strategic corporate venture capital arm of Alexandria Real Estate Equities, Inc. (NYSE: ARE), a publicly traded Real Estate Investment Trust founded in 1996 and headquartered in Pasadena, California. Since inception, Alexandria Ventures has deployed equity capital into early-stage and growth-stage life science companies developing transformative new modalities, platforms, and innovative medicines — operating from a base of 501-1,000 employees embedded across eight major U.S. life science innovation clusters (Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, New York City, and Pasadena). As of December 31, 2022, the venture portfolio carried $506 million in on-balance-sheet unrealized gains on a $1.2 billion adjusted cost basis.

The firm functions as a direct equity investor, typically participating as a strategic non-lead investor in Series A and Series B rounds alongside tier-1 specialist venture firms (Sutter Hill, ARCH Venture Partners, Deerfield, Lux Capital, Third Rock, The Column Group). Recent disclosed deployments span radioligand therapy (ARTBIO, $132M Series B), in vivo CAR-T (CREATE Medicines, $122M Series B), molecular glues (Neomorph, $100M Series B), neural-circuit immunology (Nilo Therapeutics, $101M Series A), SH2-domain inhibitors (Recludix Pharma, $123M total equity), Treg biology (TRexBio), precision diagnostics (Precede Biosciences), AI-driven drug discovery (Fathom Therapeutics), precision oncology organoids (Xilis), and migraine biologics (Vedana Therapeutics). Alexandria has been ranked the #1 most active corporate investor in biopharma by deal volume for six consecutive years by Silicon Valley Bank and a top-5 most active U.S. investor in agrifoodtech for three consecutive years by AgFunder.

Alexandria Ventures does not publish pricing or fee terms; investment economics are negotiated privately with portfolio companies. The unit generates economic value through capital appreciation and exits rather than direct revenue — segment revenue is not separately disclosed by the parent REIT. The venture arm's strategic purpose is layered: provide growth capital to biotech innovators, generate equity returns for the REIT's balance sheet, build relationships with serial entrepreneurs and academic institutions, and surface prospective tenants for ARE's labspace portfolio. Distribution channels include the Alexandria Summit® thought-leadership platform (founded 2011), the Alexandria Megacampus™ real estate brand, and direct co-investor syndication.

Name

Alexandria Venture Investments

Legal name

Alexandria Real Estate Equities, Inc.

Website

https://are.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Alexandria Venture Investments is the corporate venture capital arm of Alexandria Real Estate Equities (NYSE: ARE), deploying equity into early- and growth-stage life science companies since 1996 across eight U.S. biotech innovation clusters, ranked the #1 most active corporate biopharma investor by SVB.

Ownership category

akta.pro rank

Product category

Life Science Venture Capital

NAICS

Other Investment Pools and Funds (5259), Miscellaneous Financial Investment Activities (523999)

SIC

Investors, Nec (6799), Real Estate Investment Trusts (6798)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Real Estate Investment Management (Acquisitions & Dispositions) (BPAJAMAK)

Keywords

• Venture capital investing
• Life science investments
• Biotech venture funding
• Corporate venture capital
• Early stage biotech

Headquarters

HQ city

Pasadena

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Venture Capital Returns: Alexandria Ventures generates returns through equity investments in early-stage and growth-stage life science companies. The platform provides capital to biotech ventures and realizes gains through exits, IPOs, and follow-on investments. As of December 31, 2022, the portfolio had $506 million in on-balance sheet unrealized gains and $1.2 billion in adjusted cost basis.

Distribution channels1 record

Marketing channels2 records

Core offering

Alexandria Venture Investments (Alexandria Ventures®) is the strategic venture capital platform of Alexandria Real Estate Equities, Inc., providing equity capital to disruptive life science companies advancing transformative new modalities, platforms, and innovative medicines. Since 1996, the firm has invested across early-stage and growth-stage biotechnology, pharmaceutical, and life science technology companies, generating returns through equity appreciation, exits, IPOs, and follow-on investments.

Product overview

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT). The company operates through two primary product lines: (1) Alexandria Ventures® - a venture capital platform that has invested in disruptive life science companies since 1996, ranked as the #1 most active corporate investor in biopharma for six consecutive years, and (2) ARE® Real Estate / Alexandria Megacampus™ - a commercial real estate platform providing essential labspace infrastructure across seven major innovation clusters in the U.S. The company also offers thought leadership through the Alexandria Summit® platform and maintains a comprehensive corporate responsibility program focused on environmental sustainability and community impact.

Differentiator

Problem solved

Functional benefit

Brands

• Alexandria Lifeline™: Unique access program providing employees and their immediate family members with access to specialized medical care when faced with serious illnesses or injuries through Alexandria's world-class life science and healthcare network.
• Operation CARE
• Alexandria Summit®
• Alexandria Megacampus™

Products and services

• Alexandria Ventures® (Venture Capital Investment Platform)
• Alexandria Summit®

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Foundation for the National Institutes of Health (FNIH)coreStrategic or Co-development Partner · 22 October 2025Alexandria Real Estate Equities and Alexandria Venture Investments were awarded the 2025 Charles A. Sanders, MD, Partnership Award by the FNIH for leadership in the MAP-D public-private partnership to develop a precision medicine framework for depression, with the first phase launching in May 2026.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pfizer Ventures: Pfizer's corporate venture capital arm investing across biopharma and life sciences, frequently co-invests alongside Alexandria Ventures (e.g., TRexBio). Direct peer given identical CVC-in-life-sciences model.
• Amgen Ventures: Amgen's corporate venture arm investing in early- and growth-stage biopharma companies. Closely comparable to Alexandria's strategy of non-lead participation in life science financings.
• Novartis Venture Fund: Novartis's corporate venture fund investing in innovative life science therapeutics and platforms. Direct peer given pharma-CVC mandate and focus on transformative modalities.
• Roche Venture Fund: Roche's corporate venture arm backing innovative diagnostics and therapeutics companies. Direct peer given pharma-CVC structure and life science investment thesis.
• Sanofi Ventures: Sanofi's strategic corporate venture capital arm investing in biopharma and digital health. Comparable to Alexandria given focus on innovative medicines and platform companies.
• Johnson & Johnson Innovation: J&J's broad innovation and venture arm investing across pharmaceuticals, medtech, and consumer health. Direct peer with overlapping co-investments (e.g., TRexBio) and life science focus.
• Eli Lilly (Strategic Investments): Eli Lilly participates as a strategic corporate investor in life science financings, including TRexBio and Recludix alongside Alexandria Ventures. Direct peer given overlap in biotech investment mandates.

Broad incumbents

• ARCH Venture Partners: One of the most established U.S. life science VCs, often leading rounds in which Alexandria participates (e.g., CREATE Medicines). Comparable as a leading life science VC, though Alexandria is corporate and ARCH is independent.
• Flagship Pioneering: Premier life science innovation foundry creating and backing breakthrough platform companies. Comparable given focus on transformative new modalities and platforms in life sciences.
• OrbiMed Advisors: Large healthcare-focused investment firm across private equity, venture, and public equity strategies. Broad incumbent investing across biopharma, medical devices, and diagnostics at stages comparable to Alexandria's portfolio.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=U8w_7HgkkZ8
• LinkedInlinkedin.com/company/alexandria-real-estate-equities-inc-

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments325 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alexandria Venture Investments